Gene Therapy Approach Restores Insulin Production in Diabetic Primates: Genprex's Latest Breakthrough

Genprex Inc. (GNPX) has unveiled promising preclinical findings for GPX-002, a novel gene therapy designed to address Type 2 diabetes by rejuvenating dysfunctional beta cells. The treatment leverages an adeno-associated virus (AAV) vector to introduce Pdx1 and MafA genes directly into pancreatic tissue, targeting the root cause of insulin deficiency in Type 2 diabetes patients.

Clinical Evidence from Primate Models

In a groundbreaking non-human primate study, two animals with severe Type 2 diabetes received GPX-002 through different delivery methods. The first primate underwent intraductal infusion, which triggered progressive improvement in glucose metabolism. After seven months, this animal achieved normal glucose tolerance levels—a remarkable outcome given its baseline diabetic condition. The second primate, treated via direct pancreatic injection, experienced substantial gains, though fell short of complete normalization.

These divergent outcomes point to a critical discovery: intraductal infusion appears superior for effectively targeting both alpha and beta cells within the pancreas. Researchers also identified that immunosuppression protocols become essential for AAV-based therapies in primates, with immune reactions typically resolving within roughly six months following treatment initiation.

Rapid Response in Rodent Studies

Parallel experiments in Type 2 diabetic mice demonstrated equally compelling results. Treated animals exhibited enhanced glucose-stimulated insulin secretion and reversal of high blood sugar levels. Within four weeks post-treatment, glucose levels normalized, confirming that beta cells can indeed be functionally restored through this genetic approach.

Expanding Beyond Type 1 Diabetes

Genprex’s earlier research proved GPX-002 could convert alpha cells into functional insulin-producing beta-like cells in Type 1 diabetes models. The current Type 2 diabetes data significantly broadens the therapy’s clinical relevance, as Type 2 represents a substantially larger patient population globally.

Next Steps and Market Response

The company is accelerating non-human primate studies across both diabetes types and preparing formal toxicology assessments in preparation for an eventual Investigational New Drug application.

Market sentiment has responded positively to these developments. GNPX closed the previous trading session at $1.80, reflecting a 0.86% gain, while pre-market activity pushed the stock to $1.90, up 5.55%—signaling investor confidence in the therapy’s potential to address the significant unmet medical need in beta cell regeneration.